Neuroprotective effect of *Rhodiola rosea* Linn against MPTP induced cognitive impairment and oxidative stress

Reenu Jacob, Nalini G. and Chidambaranathan N.

Dept of Pharmacology, K. M. College of Pharmacy, Madurai, Tamilnadu, INDIA

**KEY WORDS**
- Parkinson’s disease
- Oxidative stress
- *Rhodiola rosea*
- MPTP
- Neurotoxicity

**ABSTRACT**

**Background:** Ageing and age-related neurodegenerative changes including Parkinson’s disease are characterized by an important role of reactive oxygen species. It is characterized by signs of major oxidative stress and mitochondrial damage in the pars compacta of substantia nigra. **Purpose:** Present study was designed to investigate whether *Rhodiola rosea* extract would prevent MPTP induced neurotoxicity in Male wistar rats. **Methods:** Male Wistar rats were divided into following five groups: Group I received vehicle (saline (10 ml/kg for 21 days) orally); Group II received *Rhodiola rosea* extract (250 mg/kg for 21 days) orally; Group III was treated with 20 mg/kg MPTP i.p. for 21 days; Group IV received 20 mg/kg MPTP, i.p. along with 100 mg/kg *Rhodiola rosea* orally for 21 days. Group V received 20 mg/kg MPTP i.p. along with 250 mg/kg *Rhodiola rosea* orally for 21 days. **Results:** MPTP induced rats showed behavioral alterations in elevated plus maze testing. Group III rats elicited significant increase in lipid hydroperoxide along with reduction in level of glutathione peroxidase, catalase, superoxide dismutase and total antioxidants. Histological evidence revealed that MPTP treated rats shown pathological changes like cellular inflammation and vascular degeneration in brain tissue. **Conclusion:** The oxidative stress and related biochemical alteration by MPTP were attenuated by *Rhodiola rosea* treatment. However, further studies may be necessary to elucidate the precise mechanism to support the clinical use of a plant source as antiparkinsonism drug.

**Introduction**

Parkinson’s disease is a common and debilitating age-associated human neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and degenerating projecting nerve fibres in the striatum which leads to extrapyramidal function. It is typified by four cardinal features such as bradykinesia, tremor, rigidity and postural instability. Oxidative stress plays an important role in the pathology of parkinson’s disease. It alters the mitochondrial function and increases the production of reactive oxygen species. Generation of high levels of reactive oxygen species and downregulation of antioxidant mechanisms results in cell death during ageing and age related neurodegenerative disorders including Parkinson’s disease. 1-methyl, 4 phenyl 1,2,3,6 tetrahydropyridine (MPTP) is a potent neurotoxin that induces PD in various experimental animals including monkeys, mice, cats, dogs, rats and goldfish. *Rhodiola rosea* is a highly lipophilic molecule crosses the blood brain barrier in a matter of seconds of systemic injection. It is taken up into astrocytes where it is metabolized to MPP⁺ by monoamine oxidase-B. MPP⁺ is taken up by dopamine neurons and causes a complex +I defect similar to that of Parkinson’s disease. MPTP was used in the current study to mimic PD in rats which was then subjected to neuroprotective treatment. *Rhodiola rosea* belongs to the plant family crassulaceae (golden root) is widely distributed at high altitudes in the Arctic and mountainous regions throughout the Europe and Asia. It is a popular plant of traditional medical systems in Eastern Europe and Asia, with a reputation of stimulating the nervous system, decreasing depression, enhancing work performance, eliminating fatigue, and preventing high altitude sickness. The roots and rhizomes of *Rhodiola rosea* are mainly responsible for pharmacological activity. The extracts of roots of *R. rosea* produce favorable changes in a variety of diverse physiological functions, including neurotransmitter levels, central nervous system activity and cardiovascular function. The phytochemistry of Rhodiola rosea root has revealed the presence of about 28 compounds classified into 6 distinct groups such as phenylpropanoids (rosavin, rosin, rosin), phenyl ethanol derivatives (salidroside (rhodioloside), tyrosol), Flavanoids (rodolin, rodinin, rodiosin, acetylrodalgin, tricin, Monoterpenes (ros- iridol, rosaridin), Triterpenes (daucosterol, beta-sitosterol) Phenolic acids (chlorogenic and hydroxycinnamic, gallic acids). Extracts of the *R. rosea* root also contain powerful adaptogens which protected animals and humans against mental and physical stress, toxics, and cold. Salidroside, a phenyl propanoid derivative was reported to have adaptogenic properties. *p*-tyrosol, phenolic acids such as gallic acid, caffeic acid, and chlorogenic acid, and flavonoids were reported to have antioxidant properties. With this evidence the neuroprotective action of Rhodiola rosea was investigated on MPTP rat model. Antioxidant compounds isolated from Rhodiola rosea are *p*-tyrosol, organic acids such as gallic acid, caffeic acid and chlorogenic acid, and flavonoids such as catechins and proanthocyanidins. Significant free radical scavenging activity has been demonstrated from alcohol and water extracts of Rhodiola rosea is due to the presence of variety of antioxidant compounds.

**Methods**

Healthy male Wistar rats of 250-300 gm were used for the study. Animals were purchased from Govt Medical College, Thiruvananthapuram, Kerala, India and maintained under constant temperature with free access to animal food and water ad libitum. Animal ethical clearance was taken from the institute animal ethical committee and this study was conducted according to Animal Ethics Committee guidelines of our Institution.

**Chemicals**

MPTP-HCl was purchased from Sigma Aldrich, USA. Plant drug was used for the study, *Rhodiola rosea* (RR) capsule extract was obtained from Biovea, Kensington, London. Commonly extract of *Rhodiola rosea* is available as capsules or tablets. All the chemicals used for the study was of analytical grade.
Rats used for the experiment were segregated into 5 groups with six animals in each group. Group I received normal saline 10 ml/kg orally (Control). Group II received 250mg/kg body weight of extracts orally for a period of 21 days (Drug control group). Group III received 20mg/kg body weight of MPTP administered intraperitoneally (PD model) for 21 days. Group IV received 20mg/kg body weight of MPTP along with 100mg/kg body weight of Rhodiola rosea extract (Low dose treatment group). Group V received 20mg/kg body weight of MPTP along with 250 mg/kg body weight of Rhodiola rosea extract (High dose treatment group). The drug Rhodiola rosea available in the form of Capsule. Each Capsule contains 300mg of Rhodiola rosea. For calculating 250mg/kg dose i.e. 250/1000 × 200 = 50mg. For one rat 50mg of extract is needed. Here six rats are used for study. So 6 × 50 = 300mg needed for 6 rats. 10 capsules were used for making solution. It means 10 capsules contain 3000mg powder. Then it was diluted to 30ml vehicle. 1ml of solution contains 100mg of extract. 0.5 ml of solution contains 50mg. For 100mg/kg dose i.e. 100/1000 × 200 = 20mg. For one rat 20 mg of extract is used. So 6 × 20 = 120mg needed for 6 rats. 5 capsules were used for preparation of drug solution. No of capsules i.e. 5 X weight of one capsule means 1500 mg for 20 ml solution. 1ml solution contains 75mg. 0.3 ml solution contains around 20mg. Behavioural studies was performed 2 weeks after MPTP treatment. Animals were sacrificed on 21st day of experimental protocol.

**Behavioural studies**

**Elevated plus maze test**

The elevated plus maze consisted of two opposite black open arms (50 × 10 cm), crossed with two closed walls of the same dimensions with 40 cm high walls. The arms were connected with a central square of dimensions 10 × 10 cm. The entire maze was elevated to a height of 50 cm from the floor. Acquisition of memory was tested on day 13 after MPTP administration. Animal was placed individually at one end of the open arm facing away from the central square. The time taken by the animal to move from the open arm to the closed arm was recorded as the initial transfer latency (ITL). Animal was allowed to explore the maze for 20 seconds after recording the ITL and then returned to the home cage. If the animal did not enter the enclosed arm within 90 seconds, it was guided on the back into one of the enclosed arm and the ITL was given as 90 seconds. Retention of memory was assessed by placing the rat in an open arm and the retention latency was noted on day 14 and day 21 of ITL and termed as the first retention transfer latency (1st RTL) and second retention transfer latency (2nd RTL), respectively.

**Locomotor activity**

Locomotor disability was measured using an Instrument called Actophotometer. The movement of animal cut off a beam of light falling on Photocell and count was recorded and displaced digitally. Each rat was placed individually in the actophotometer for 10 minutes and basal activity scores were recorded. Gross behaviour activity was observed on 14th and 21st day after MPTP injection. The animals were observed for a period of 10 minutes and values were expressed as counts/10 minutes.

**Tissue collection**

On completion of experimental period, animals are sacrificed by euthanasia under ketamine Anaesthesia. Brain tissues are excided immediately and immersed in ice cold saline. The tissues were homogenized in 0.01 M phosphate buffer solution of Ph7.4 using glass homogenizer. The homogenate was centrifuged at 12000 rpm for 20 minutes, 4°C to obtain the post mitochondrial supernatant (PMS) which was used for used for analyzing various biochemical parameters. The tissue homogenate was stored at -20°C until further use.

**Histopathological analysis**

Mid portion of the brain specimens obtained from all groups of animals were fixed in 10% formalin. The tissue sections were embedded in Paraffin wax and sectioned at 5-6 μm thickness and sections were stained with Haematoxylin and eosin method for photomicroscopic observation of the brain histopathological architecture.

**Biochemical analysis**

From the homogenate samples glutathione peroxidase, catalase, superoxide dismutase were assayed using Elisa Kits. The level of lipid peroxides were estimated by the method of Ohkawa et al.

**Statistics**

The statistical analysis was carried using Graph pad Instat software of version 3. Hypothesis testing methods included one way analysis of variance followed by Newman Keul’s Multiple range test. P values less than 0.01 was considered to statistical significance. All these results were expressed as mean ± SE for six animals in each group.

**Results**

Table I shows Rhodiola rosea improved on behavioural alterations in MPTP treated rats; The mean initial transfer latencies (ITL) on day 13 for each rat was relatively stable and showed no significant variation among different groups. Mean retention transfer latencies (1st RTL and 2nd RTL) to enter closed arm on day 14 and 21 were shorter as compared to ITL on day 13 of each group, respectively. MPTP injected rats did not show any change in the mean retention time transfer latencies on day 14 and 21 as compared to the pre training latency on day 13, demonstrating that MPTP induced marked memory impairment. Chronic Administration of RR (100 mg & 250 mg/kg) beginning prior to MPTP injection significantly decreased mean retention latencies on day 14 & 21 following MPTP injection (p<0.01).

Table 2 shows antioxidant status; LPO levels in the brain tissue homogenate were significantly elevated (P<0.01) and reduction in the activities of SOD, catalase, glutathione peroxidase and total antioxidants in MPTP treated animals (Group III) relative to controls. RR (250 mg/kg) administration of MPTP treated animals tend to bring the SOD, CAT, GPx and TA levels close to normal values. No significant were found in rats treated with RR alone.

Table 3 shows effect on locomotor activity. The mean scores of locomotor activity for each rat were more relatively stable and showed no significant variation among different groups. The mean scores in normal control, perse control and MPTP treated rats remain unchanged. Further, both the dose of RR
### Table 1: Assessment of Cognitive performance in MPTP treated rats

| Groups   | Treatment                                           | Mean transfer latency (sec) |
|----------|-----------------------------------------------------|-----------------------------|
|          |                                                     | ITL | 1st RTL | 2nd RTL |
| Group I  | Normal control (10 ml/kg. N. Saline)                | 60.10 ± 2.08                | 21.6 ± 1.90     | 22.0 ± 1.60     |
| Group II | Perse control (250 mg/kg of R. R)                   | 64.6 ± 2.16                 | 19.4 ± 1.82     | 18.0 ± 1.72     |
| Group III| Toxic control (20 mg/kg of MPTP)                    | 68.77 ± 2.62                | 82.30 ± 3.40**  | 80.6 ± 3.16**  |
| Group IV | Treatment I/Low dose treatment (100 mg/kg R. R + MPTP)| 65.6 ± 2.12                 | 48.60 ± 2.52**  | 43.4 ± 2.06**  |
| Group V  | Treatment II/High dose treatment group (250 mg/kg RR + MPTP) | 66.6 ± 2.30 | 38.4 ± 2.42** | 34.2 ± 1.92** |

Statistical significance was represented as P<0.01. a** Group III compared with Group I and Group II. b* Group IV compared with Group III. b** Group V compared with Group III.

### Table 2: Antioxidant status in homogenate of brain tissues.

| Groups   | Lipid hydroperoxide LPO (nmol/mg of protein) | Total antioxidants TA (mM/mg of protein) | Glutathione Peroxidase GPx (nmol/min/mg of protein) | Catalase CAT (μM/mg of protein) | Superoxide dismutase (units/mg of protein) |
|----------|---------------------------------------------|------------------------------------------|--------------------------------------------------|---------------------------------|------------------------------------------|
|          |                                             |                                          |                                                  |                                 |                                          |
| Group I  | 3.03 ± 0.10                                 | 3.27 ± 0.30                              | 23.8 ± 1.38                                      | 48.60 ± 3.32                    | 35.73 ± 3.19                             |
| Group II | 2.51 ± 0.30                                 | 3.10 ± 0.16                              | 26.18 ± 1.95                                     | 53.80 ± 4.23                    | 33.02 ± 1.05                             |
| Group III| 4.24 ± 0.25**                               | 1.57 ± 0.15**                           | 12.65 ± 1.83**                                   | 31.26 ± 2.84**                  | 9.82 ± 0.58**                            |
| Group IV | 2.13 ± 0.13**                               | 2.38 ± 0.15**                           | 20.46 ± 2.6**                                    | 44.78 ± 2.39**                  | 19.17 ± 1.47**                           |
| Group V  | 2.52 ± 0.15**                               | 2.77 ± 0.13**                           | 22.01 ± 1.56**                                   | 47.49 ± 2.24**                  | 23.03 ± 1.97**                           |

Statistical significance was represented as P<0.01. a** Group III compared with Group I. b* Group IV compared with Group III, Group V compared with Group III.

### Table 3: Table demonstrating locomotor activity of different treatment groups

| GROUPS         | TREATMENT       | Locomotor activity (score) in 10 min±SEM on 14th day 21st day |
|----------------|-----------------|---------------------------------------------------------------|
| GROUP I        | Normal Control  | 218 ± 12.85                                                  | 220.00 ± 11.45 |
| GROUP II       | Perse Control   | 207.5 ± 10.20                                                 | 212.40 ± 10.40 |
| GROUP III      | Toxic Control   | 222.4 ± 13.4                                                  | 232.6 ± 12.40  |
| GROUP IV       | Low dose treatment group | 201.5 ± 9.6 | 228.4 ± 11.0   |
| GROUP V        | High dose treatment group | 230.4 ± 12.4 | 230.5 ± 12.6  |

(100 mg&250 mg/kg) did not cause any significant activations in the locomotor activity as compared to MPTP treated rats on day 14&21.

Histopathological studies of midbrain (Figure 1) (1). Histopathological study of midbrain portion is considered because Substantia nigra is a part of the midbrain which contains a large number of dopamine producing neurons. MPTP is a site specific toxin which damages the dopamine producing neurons in substantia nigra viewed under light microscope in control and experimental animals. Haematoxylin/eosin staining of paraffin sections (100 XH&E). A: Section of brain from rats treated with normal saline

Fig. 1: A portion of the midbrain where substantia nigra is located stained with Haematoxylin and eosin viewed under light microscope (100 X H&E). A: Rats treated with Normal Saline for 21 days. B: Rats treated with 250 mg/kg body weight of Rhodiola rosea for 21 days (perse control). C: Rats treated with 20 mg/kg MPTP for 21 days. D& E: Rats treated with MPTP for 21 days followed by RR treatments.
for 21 days showing normal architecture. B: Section of brain from rat treated with 250 mg/kg body weight of *Rhodiola rosea* for 21 days (perse control) showing normal architecture. C: section of brain from rats treated with MPTP for 21 days showing pathological changes like cellular inflammation, vascular degeneration and cytoplasmic vacuolation. D & E: Section of brain from rats treated with MPTP for 21 days followed by RR treatments showing marked reduction of degeneration and vacuolation.

**Discussion**

There is a growing evidence that oxidative stress and mitochondrial respiratory failure with attendant decrease in energy output are implicated in neuronal death in PD. MPTP is believed to induce selective toxicity at central dopaminergic neurons via the end products of its oxidation, 1-methyl-4-phenylpyridinium (MPP⁺) which inhibits oxidative metabolism at complex I of the mitochondrial respiratory chain by its specific inhibition of NADH-ubiquinone oxidoreductase. Although the mechanism by which it induces selective dopaminergic cell death has not been fully elucidated, it was described that MPTP acts as an inhibitor of Complex-I of mitochondrial respiratory pathway and produces a decrease in tissue ATP content and increases ROS formation. Certain brain regions like striatum and pathway and produces a decrease in tissue ATP content and in neuronal death has not been fully elucidated, it was described that MPTP may be attributed to the nitrigenomic phenolic compounds present which are good antioxidants. 

MPTP when given intraperitoneally could offer a useful support to the Parkinsonism therapy by acting as a neuroprotective antioxidant and thus prevent the neuronal damage in brain regions associated with Parkinsonism. Thus RR extract enriched with bioflavonoids polyphenols and triterpenes may be considered as a powerful neuroprotective agent for membrane molecular medicine. Further studies may be necessary to elucidate the exact molecular mechanisms of actions of the various constituents in RRE against MPTP induced excitotoxicity.

**Acknowledgements**

The authors are thankful to Management and Dr. M. Nagarajan, Chairman, K. M. College of pharmacy, Madurai for providing necessary facilities for carry out this research work.

The article complies with International Committee of Medical Journal editor’s uniform requirements for manuscript.

Conflict of Interests: None, Source of funding: K. M. College of pharmacy, Madurai

Received Date : 4 December, 2012; Revised Date : 18 January, 2013; Accepted Date : 28 February, 2013

**References**

1. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson’s disease. Adv. Neurol 1987; 45: 19–34.
2. Agid Y. Parkinson’s disease. Pathophysiology Lancet 1991; 337: 1321–1324.
3. Tillerson JL, Miller GW. Grid performance test to measure behavioral impairment in the MPTP treated mouse model of Parkinsonism. J Neurosci Methods 2003; 123: 189–200.
4. Oida Y, Kitachi K, Nakayama H, et al. Rifampicin attenuates the MPTP induced neurotoxicity in mouse brain. Brain Res 2006; 1082: 196–204.
5. Bodis-Wollner L, Chung E, Gihardiri MF, et al. Acetyly-Levo-carantin protects against MPTP-induced Parkinsonism in primates. J. Neural. Transm. Park. Dis. Dement 1991; 3: 63–72.
6. Gerlach M, Riederer P, Przuntek H, et al. MPTP mechanisms of neurotoxicity and their implications for Parkinson’s disease. Eur. J Pharmacol 1991; 208: 273–286.
7. Singer TP, Castagnoli N Jr, Rona RR, et al. Biochemical events in the development of Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem 1987; 49: 1–8.
8. Nicklas WI, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of Neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985; 36: 2503–2508.
9. Petkov VD, Stancheva SL, Mosharoff A, et al. Effects of alcohol aqueous extract from *Rhodiola rosea* L. roots on learning and memory. Acta Physiol Pharmacol Bulg 1986; 12(1): 3–16.
10. Kurkin VA, Zapsochnaya GG. Chemical composition and pharmacological Characteristics of *Rhodiola rosea* [review]. J Med Plants (Moscow) 1985: 1231–445.
11. Saratikov AS, Krasnov EA, Khnikina LA, et al. Isolation and chemical analysis of individual biologically active constituents of *Rhodiola rosea*. Proc Siberian Acad Sci Biol 1967; 1: 54–60.
12. Saratikov AS, Krasnov EA. *Rhodiola rosea* is a valuable medicinal plant (Golden Root). Tomsk, Russia: Tomsk State Univ. Press 1987.
13. Krylov GV. Herbs for Life. Novosibirsk, Russia: Academic Press. 1969; p. 264.
14. Zhang L, Yu H, Sun Y et al. Protective effect of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. European Journal of Pharmacology 2007; 564: 18–25.

15. Lee MW, Lee YA, Park HM, et al. Antioxidative phenolic compounds from the roots of Rhodiola sachalinensis A. Bor Arch Pharm Res 2000; 23: 455–458.

16. Ohsugi M, Fan W, Hase K, et al. Active-oxygen scavenging activity of traditional nourishing-tonic herbal medicines and active constituents of Rhodiola sacra. J Ethnopharmacol 1999; 67: 111–119.

17. Sharma AC, Kulkarni SK. “Evaluation of learning and memory mechanisms employing elevated plus-maze in rats and mice. Progress in Neuro Psychopharmacology and Biological Psychiatry 1992; 16(1): 117–125.

18. Thamizh TS, Uvarajan S, Vanisree AJ. Neuroprotective action of Piper longum against MPTP induced changes in mouse brain. Annals of Neurosciences 2010; 7(1): 18–21.

19. Nagaraja H, Kumar P. Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced Parkinsonism in aged Sprague-Dawley rats. The Journal of Toxicological Sciences 2010; 35(1): 41–47.

20. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxidation in animal tissues by thiobarbituric acid reaction. Anal Biochemistry 1979; 47: 456–460.

21. Jason LE, Leonard P. Parkinson’s disease – molecular mechanisms of disease. Drug Discov Today: Disease Mechanisms, CNS and PNS diseases 2004; 1: 399–405.

22. Ebadi M, Govitrapong P, Sharma S, et al. Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of Parkinson’s disease. Biol Signals Recept 2001; 10: 224–233.

23. Lan J, Jiang DH. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson’s disease. J. Neural. Transm 1997; 104: 649–660.

24. Hill JM, Switzer RC. The regional distribution and cellular localization of iron in the rat brain. Neuroscience 1984; 11: 595–603.

25. Iczkiewicz J, Jackson MJ, Smith LA, et al. Osteopontin expression in substantia nigra in MPTP treated primates and in Parkinson’s disease. Brain Res 2006; 1118: 239–250.

26. Annunziato L, Amoroso S, Pannaccione A, et al. Apoptosis induced in neuronal cells by oxidative stress: role played by caspases and intracellular calcium ions. Toxicol. Lett 2003; 139: 125–133.

27. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16: 439–444.

28. Saija A, Scalese M, Lanza M, et al. Flavanoids as antioxidant agents: importance of their biomembranes. Free Radic. Biol. Med 1995; 19: 481–486.

29. Rice-Evans CA, Miller NJ, Bolwell PG, et al. The relative antioxidant activities of plant derived polyphenolic flavanoids. Free Radic. Res 1995; 22: 375–383.

30. Crocker SJ, Smith PD, Jackson-Lewis V, et al. Inhibition of Calpains Prevents Neuronal and Behavioural Deficits in an MPTP model of Parkinson’s disease. The Journal of Neuroscience 2003; 23(10): 4081–4091.